MAPT rs1800547 — The Molecular Switch in Tau's H1/H2 Divide
Within the microtubule-associated protein tau (MAPT) gene on chromosome 17q21,
a single nucleotide difference at rs1800547 marks one of the most consequential
forks in human neurological risk: the ancient H1/H2 haplotype boundary. While the
broader H1/H2 distinction spans a 900-kilobase chromosomal inversion, rs1800547
is the canonical SNP that directly differentiates the H1 and H2 clades | The GenePD
Study found rs1800547 was the single most statistically significant variant in the
region for Parkinson's disease after multiple testing correction.
Unlike rs17649553, which is another H1/H2 tag in the region, rs1800547 has been
shown to have direct molecular function — not merely a passive marker of haplotype
membership.
The MAPT gene produces tau, a protein whose primary job is stabilizing the neuronal
microtubule skeleton and supporting axonal transport. When tau becomes hyperphosphorylated
and misfolds, it aggregates into neurofibrillary tangles, the pathological hallmark
of tauopathies including Alzheimer's disease, Parkinson's disease, progressive
supranuclear palsy (PSP), and corticobasal degeneration (CBD).
The Mechanism: Splice Factor Binding and Exon 3
A landmark 2017 study using whole-locus MAPT expression vectors demonstrated that
rs1800547, working together with rs17651213, directly controls haplotype-specific
inclusion of MAPT exon 3 | Exon 3 encodes a region of the N-terminal projection
domain of tau that affects its interaction with membranes and the neuronal cytoskeleton.
Using electrophoretic mobility shift assays, researchers found that the H1 (A) and
H2 (G) alleles at rs1800547 create distinct RNA-protein binding patterns with
splicing factors hnRNP F and hnRNP Q — critical regulators of alternative splicing
in neurons. The H2 sequence at this position allows 1.76-fold higher exon 3 inclusion
compared to H1, altering the proportion of N1 and N2 tau isoforms.
This matters because the balance of tau isoforms — not just total tau levels — appears
critical to which tauopathy, if any, develops. H1 is associated with elevated 4-repeat
(4R) tau isoforms, which are the primary constituents of pathological aggregates in
PSP and CBD. H2's different splicing pattern may shift the balance away from
aggregation-prone 4R isoforms.
The Evidence for Parkinson's Disease
The GenePD Study genotyped 21 SNPs across the MAPT region in PD families and
controls, finding that rs1800547 emerged as the most statistically significant
variant for PD association, surviving multiple testing correction | The study also
found 4-repeat MAPT isoforms significantly elevated in PD brains (p=0.002),
linking the H1 splicing signature to disease pathology.
A large case-control study of 1,762 PD patients and 2,010 controls found that
H1/H1 homozygotes had an odds ratio of 1.46 (95% CI 1.25–1.69, p=8×10⁻⁷) for PD
compared to H1/H2 and H2/H2 carriers | The association held across familial and
sporadic disease, both sexes, and early- and late-onset subgroups.
Progressive Supranuclear Palsy: The Strongest Association
The H1/H1 genotype is found in approximately 94% of PSP patients compared to ~64%
of the general population — a striking enrichment. A JAMA Neurology study of 802
neuropathologically confirmed PSP cases identified H1 subhaplotypes with markedly
elevated risk: H1d (OR 1.86), H1g (OR 3.64), and H1o (OR 2.60) | These sub-haplotype
associations suggest that specific combinations of H1-background variants, on top of
the rs1800547 A allele, determine the magnitude of PSP risk.
The chromosome 17q21.31 region — anchored by rs1800547 — represents the single
strongest genetic risk locus for PSP identified to date.
Alzheimer's Disease: A Different Pathway
A study of 17,996 participants (8,559 AD cases, 9,437 controls) across Spanish and
international cohorts found that rs1800547 itself was associated with AD risk (OR 1.12,
p=0.0025) | The effect was strongest in APOE ε4 non-carriers — suggesting MAPT H1
represents an alternative causal pathway to AD distinct from amyloid-driven disease.
The risk was highest in individuals over age 77 without APOE ε4 (p=0.001), suggesting
a late-life tau-driven pathway independent of beta-amyloid accumulation. For people
without the APOE ε4 allele, the MAPT H1 haplotype tagged by rs1800547 becomes a
more prominent contributor to AD risk.
ALS and Frontotemporal Spectrum
Beyond the primary tauopathies, a 2023 study of Bulgarian ALS patients found the
H1b subhaplotype (containing the rs1800547 A allele) conferred a nearly 2-fold
increased risk for sporadic ALS | The authors propose that fine transcriptional
regulation at the MAPT locus, including rs1800547's splice factor interactions,
may influence ALS susceptibility through shared tau biology with FTD.
ALS and FTD share genetic and pathological overlap, and MAPT variation may
contribute to the clinical spectrum between them.
Practical Actions
For H1/H1 carriers (AA genotype), the relevant clinical considerations are monitoring
for motor symptoms that might indicate early parkinsonism, PSP, or CBD — conditions
where early specialist evaluation matters for accurate diagnosis and prognosis. PSP
in particular is frequently misdiagnosed as Parkinson's disease but responds differently
to treatment. For the Alzheimer's disease risk — especially relevant for APOE ε4
non-carriers — knowing your MAPT status can help contextualize the late-life cognitive
monitoring picture.
There are currently no approved pharmacological agents specifically targeting MAPT
splicing or H1-driven tau isoform imbalance, though several anti-tau therapies are
in clinical trials. Lifestyle factors — particularly aerobic exercise and head trauma
prevention — have independent evidence for neuroprotection across multiple pathways
relevant to tauopathy risk.
Interactions
rs1800547 and rs17649553 both tag the same H1/H2 haplotype and are in very strong
linkage disequilibrium. If a person's genome contains both SNPs, their results should
be concordant. The H1 risk at this locus compounds with rs356182 (SNCA) for
Parkinson's disease risk — though interaction analyses have found these act
independently rather than epistatically. In Alzheimer's disease, the H1/H2
distinction interacts with APOE genotype (rs429358), with H1 risk most pronounced
in APOE ε4 non-carriers.
All Genotypes
One copy each of H1 and H2 — intermediate tauopathy risk, partial H2 protection
You carry one copy of the H1 haplotype (A allele) and one copy of the protective H2 haplotype (G allele). This heterozygous genotype is found in approximately 32% of people of European descent. Your risk for Parkinson's disease, PSP, and corticobasal degeneration is intermediate — lower than H1/H1 but not as low as H2/H2. Having one H2 copy partially attenuates the splicing shift toward 4-repeat tau isoforms, providing some protection against the 4R tauopathies. For Alzheimer's disease, your risk also falls between the two homozygous genotypes. The magnitude of protection from a single H2 copy is meaningful but not complete.
Two copies of the H1 haplotype — elevated risk for Parkinson's, PSP, CBD, and Alzheimer's disease
You carry two copies of the H1 haplotype at this canonical MAPT haplotype-defining position. The AA genotype is the ancestral and most common form, shared by approximately 64% of people of European descent. The H1/H1 genotype drives higher production of 4-repeat tau isoforms through altered exon 3 splicing, increasing susceptibility to several neurodegenerative tauopathies. H1/H1 confers an odds ratio of about 1.46 for Parkinson's disease and is found in approximately 94% of progressive supranuclear palsy patients (versus ~64% in the general population). The H1 haplotype also independently increases Alzheimer's disease risk (OR ~1.12), particularly in people who do not carry the APOE ε4 allele — suggesting a tau-driven pathway to AD distinct from amyloid-driven disease. Most H1/H1 individuals never develop these conditions; genetic risk is one of many contributors.
Two copies of the protective H2 haplotype — substantially reduced risk for most tauopathies
You carry two copies of the protective H2 haplotype at this MAPT haplotype-defining position. The GG genotype is found in approximately 4% of people of European descent and is rare in East Asian (<0.1%) and African (~0.2%) populations. H2/H2 is associated with substantially reduced risk for Parkinson's disease, progressive supranuclear palsy, and corticobasal degeneration compared to H1/H1 carriers. The G allele at rs1800547 creates different hnRNP F/Q binding sites that favor higher exon 3 inclusion in MAPT transcripts, shifting tau isoform production away from the aggregation-prone 4-repeat forms predominant in PSP and CBD. Meta-analyses estimate an overall odds ratio of about 0.78 for Parkinson's disease in H2 carriers. For PSP, H2/H2 individuals are markedly underrepresented in patient populations.